Loading
Biomark Diagnostics Inc. Stock: price and insider trades · Canada
Biomark Diagnostics Inc.: what insiders have been doing
This page follows insider dealings at Biomark Diagnostics Inc. as filed with SEDI, a company from the Health Care sector. The last twelve months, up to 21 October 2026, brought 69 filings signed by 3 insiders.
The flow runs one way only: 3 insiders bought (65 purchases totalling €59k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 3 senior executives. At €9,337, the purchase published on 17 July 2026 by Maula Bux, Rashid Ahmed is the largest of the period (0.028% of market cap).
For context, the typical company on the same exchange (median of 2,475 companies) published 12 filings over the same period, against 69 filings here. The full history, which starts in 2014, counts 275 purchases against no sales.
The last purchase on record was published on 16 October 2026, which is 4 days ago. The median gap between a trade and its publication by SEDI is 2 days. That lag is the time during which only the insider knows about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
309
Thresholds
n/a
Buy Volume
€238,751
275 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleRashid Ahmed Maula Bux62 buys
Guoyu Huang43 buys
James Arthur Lavender1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
CA$0.47
Analyst consensus
Income statement
RevenueCA$59.8k
EBITDA-CA$1M-1726% margin
Net income-CA$1.5M-2470.8% margin
Valuation
P/Book94.0x
Beta-0.38
Balance sheet & cash
Market capCA$50M
Total debtCA$724.9k
Free Cash Flow-CA$1.1M
Debt / Equity223%
Profitability & ownership
ROE-149.9%
ROA-45.6%
% insiders48.5%
% institutions0.0%
Last declaration on 16 October 2026
Declarations309 total
500 shares@ CA$0.500.0005% mcap1.3% of flowCommon SharesTSXSEDI:4792283
Canonical exit: 13 Jan 2027 (T+90)
1,000 shares@ CA$0.520.0010% mcap2.7% of flowCommon SharesTSXSEDI:4792282
Canonical exit: 12 Jan 2027 (T+90)
1,500 shares@ CA$0.530.0015% mcap4.1% of flowCommon SharesTSXSEDI:4792280
Canonical exit: 11 Jan 2027 (T+90)
8,500 shares@ CA$0.470.0074% mcap7.0% of flowCommon SharesTSXSEDI:4792279
Canonical exit: 14 Jan 2027 (T+90)
3,500 shares@ CA$0.480.0031% mcap2.9% of flowCommon SharesTSXSEDI:4792277
Canonical exit: 13 Jan 2027 (T+90)
1,000 shares@ CA$0.520.0010% mcap0.9% of flowCommon SharesTSXSEDI:4792276
Canonical exit: 11 Jan 2027 (T+90)
500 shares@ CA$0.550.0005% mcap1.6% of flowCommon SharesTSXSEDI:4790082
Canonical exit: 4 Jan 2027 (T+90)
500 shares@ CA$0.530.0005% mcap0.5% of flowCommon SharesTSXSEDI:4790081
Canonical exit: 7 Jan 2027 (T+90)
2,000 shares@ CA$0.550.0019% mcap2.1% of flowCommon SharesTSXSEDI:4790079
Canonical exit: 4 Jan 2027 (T+90)
1,000 shares@ CA$0.560.0009% mcap3.2% of flowCommon SharesTSXSEDI:4786391
Canonical exit: 30 Dec 2026 (T+90)
500 shares@ CA$0.550.0005% mcap1.6% of flowCommon SharesTSXSEDI:4782010
Canonical exit: 24 Dec 2026 (T+90)
1,000 shares@ CA$0.540.0010% mcap3.2% of flowCommon SharesTSXSEDI:4782009
Canonical exit: 23 Dec 2026 (T+90)
1,100 shares@ CA$0.550.0011% mcap1.2% of flowCommon SharesTSXSEDI:4782008
Canonical exit: 24 Dec 2026 (T+90)
1,000 shares@ CA$0.500.0009% mcap1.0% of flowCommon SharesTSXSEDI:4782007
Canonical exit: 22 Dec 2026 (T+90)
1,100 shares@ CA$0.500.0011% mcap0.1% of flowCommon SharesTSXSEDI:4779510
Canonical exit: 16 Dec 2026 (T+90)
1,000 shares@ CA$0.490.0009% mcap3.0% of flowCommon SharesTSXSEDI:4776959
Canonical exit: 9 Dec 2026 (T+90)
2,000 shares@ CA$0.480.0018% mcap6.0% of flowCommon SharesTSXSEDI:4776957
Canonical exit: 7 Dec 2026 (T+90)
1,500 shares@ CA$0.490.0014% mcap1.5% of flowCommon SharesTSXSEDI:4776956
Canonical exit: 10 Dec 2026 (T+90)
6,600 shares@ CA$0.460.0057% mcap6.2% of flowCommon SharesTSXSEDI:4776955
Canonical exit: 7 Dec 2026 (T+90)
1,200 shares@ CA$0.470.0011% mcap3.5% of flowCommon SharesTSXSEDI:4770128
Canonical exit: 26 Nov 2026 (T+90)
2,500 shares@ CA$0.480.0022% mcap7.4% of flowCommon SharesTSXSEDI:4770127
Canonical exit: 22 Nov 2026 (T+90)
1,300 shares@ CA$0.4950.0012% mcap1.3% of flowCommon SharesTSXSEDI:4770126
Canonical exit: 26 Nov 2026 (T+90)
4,500 shares@ CA$0.480.0040% mcap4.4% of flowCommon SharesTSXSEDI:4770125
Canonical exit: 22 Nov 2026 (T+90)
1,000 shares@ CA$0.570.0011% mcap1.2% of flowCommon SharesTSXSEDI:4767666
Canonical exit: 17 Nov 2026 (T+90)
1,100 shares@ CA$0.590.0012% mcap1.3% of flowCommon SharesTSXSEDI:4764850
Canonical exit: 12 Nov 2026 (T+90)
25 of 309 declarations
About Biomark Diagnostics Inc.
Biomark Diagnostics Inc. is a company focused on developing diagnostic tests for cancer. It aims to improve patient outcomes through innovative solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
